Literature DB >> 29959968

Current technology for the industrial manufacture of snake antivenoms.

Guillermo León1, Mariángela Vargas2, Álvaro Segura2, María Herrera2, Mauren Villalta2, Andrés Sánchez2, Gabriela Solano2, Aarón Gómez2, Melvin Sánchez2, Ricardo Estrada2, José María Gutiérrez2.   

Abstract

Snake antivenoms are formulations of animal immunoglobulins used in the treatment of snakebite envenomation. The general scheme for producing snake antivenoms has undergone few changes since its development more than a century ago; however, technological innovations have been introduced in the manufacturing process. These medicines must comply with identity, purity, safety and efficacy profiles, as requested by the current Good Manufacturing Practices (GMPs) applied to modern biopharmaceutical drugs. Industrial production of snake antivenoms comprises several stages, such as: 1) production of reference venom pools, 2) production of hyperimmune plasma, 3) purification of the antivenom immunoglobulins, 4) formulation of the antivenom, 5) stabilization of the formulation, and 6) quality control of in-process and final products. In this work, a general review of the existing technology used for the industrial manufacture of snake antivenoms is presented.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Keywords:  Antivenom; Envenomation; Industrial biotechnology; Snake; Venoms

Mesh:

Substances:

Year:  2018        PMID: 29959968     DOI: 10.1016/j.toxicon.2018.06.084

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  22 in total

1.  Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition.

Authors:  Stefanie K Menzies; Charlotte A Dawson; Edouard Crittenden; Rebecca J Edge; Steven R Hall; Jaffer Alsolaiss; Mark C Wilkinson; Nicholas R Casewell; Robert A Harrison; Stuart Ainsworth
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

2.  In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom.

Authors:  Line Ledsgaard; Andreas H Laustsen; Urska Pus; Jack Wade; Pedro Villar; Kim Boddum; Peter Slavny; Edward W Masters; Ana S Arias; Saioa Oscoz; Daniel T Griffiths; Alice M Luther; Majken Lindholm; Rachael A Leah; Marie Sofie Møller; Hanif Ali; John McCafferty; Bruno Lomonte; José M Gutiérrez; Aneesh Karatt-Vellatt
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

3.  Streamlined downstream process for efficient and sustainable (Fab')2 antivenom preparation.

Authors:  Tihana Kurtović; Marija Brgles; Maja Lang Balija; Stephanie Steinberger; Dora Sviben; Martina Marchetti-Deschmann; Beata Halassy
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-07-27

4.  Recombinant antibodies against Iranian cobra venom as a new emerging therapy by phage display technology.

Authors:  Ali Nazari; Maedeh Samianifard; Hadi Rabie; Abbas Zare Mirakabadi
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-06-19

5.  Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.

Authors:  Guillermo León; María Herrera; Mariángela Vargas; Mauricio Arguedas; Andrés Sánchez; Álvaro Segura; Aarón Gómez; Gabriela Solano; Eugenia Corrales-Aguilar; Kenneth Risner; Aarthi Narayanan; Charles Bailey; Mauren Villalta; Andrés Hernández; Adriana Sánchez; Daniel Cordero; Daniela Solano; Gina Durán; Eduardo Segura; Maykel Cerdas; Deibid Umaña; Edwin Moscoso; Ricardo Estrada; Jairo Gutiérrez; Marcos Méndez; Ana Cecilia Castillo; Laura Sánchez; Ronald Sánchez; José María Gutiérrez; Cecilia Díaz; Alberto Alape
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

Review 6.  Innovative Immunization Strategies for Antivenom Development.

Authors:  Erick Bermúdez-Méndez; Albert Fuglsang-Madsen; Sofie Føns; Bruno Lomonte; José María Gutiérrez; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-11-02       Impact factor: 4.546

7.  Refinement strategy for antivenom preparation of high yield and quality.

Authors:  Tihana Kurtović; Maja Lang Balija; Marija Brgles; Dora Sviben; Monika Tunjić; Hrvoje Cajner; Martina Marchetti-Deschmann; Günter Allmaier; Beata Halassy
Journal:  PLoS Negl Trop Dis       Date:  2019-06-17

Review 8.  Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories.

Authors:  José María Gutiérrez
Journal:  Toxins (Basel)       Date:  2018-12-24       Impact factor: 4.546

9.  Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming.

Authors:  David J Williams; Mohd Abul Faiz; Bernadette Abela-Ridder; Stuart Ainsworth; Tommaso C Bulfone; Andrea D Nickerson; Abdulrazaq G Habib; Thomas Junghanss; Hui Wen Fan; Michael Turner; Robert A Harrison; David A Warrell
Journal:  PLoS Negl Trop Dis       Date:  2019-02-21

Review 10.  Toxin Neutralization Using Alternative Binding Proteins.

Authors:  Timothy Patrick Jenkins; Thomas Fryer; Rasmus Ibsen Dehli; Jonas Arnold Jürgensen; Albert Fuglsang-Madsen; Sofie Føns; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2019-01-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.